Literature DB >> 8289097

Cholesterol-lowering therapy: what patients expect in return.

W W Reed1, J E Herbers, G L Noel.   

Abstract

OBJECTIVE: To assess variability in patients' values and preferences regarding cholesterol-lowering therapy.
DESIGN: A descriptive study. Patients currently receiving cholesterol-lowering therapy were interviewed using the time tradeoff and standard reference gamble techniques of utility assessment.
SETTING: Internal medicine clinics of a military medical center. PARTICIPANTS: Thirty-five patients, clinically free of coronary disease, receiving cholesterol-lowering therapy for at least three months.
RESULTS: When the time tradeoff method was applied, 12 (34%) of the patients indicated that less than one month of additional life would be a fair return for adhering to their current therapy for the rest of their lives, while 13 (37%) patients required more than one additional year of life, and four (11%) required at least five years. By the standard reference gamble method, 18 (51%) patients would not have accepted a risk of one in a thousand of imminent death (in 30 days) in hopes of obtaining a normal life expectancy off therapy, while 14 (40%) would have agreed to a 1% or greater risk in order to avoid therapy.
CONCLUSIONS: While many patients apparently expected very little in return for adhering to therapy, many others may not be getting "what they bargained for."

Entities:  

Mesh:

Year:  1993        PMID: 8289097     DOI: 10.1007/BF02599710

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  15 in total

1.  Content of ambulatory internal medicine practice in an academic Army medical center and an Army community hospital.

Authors:  J E Johnson; E M Pinholt; T R Jenkins; J L Carpenter
Journal:  Mil Med       Date:  1988-01       Impact factor: 1.437

2.  Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

3.  What if Americans ate less fat? A quantitative estimate of the effect on mortality.

Authors:  W S Browner; J Westenhouse; J A Tice
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

4.  Measurement of quality of life in end-stage renal disease: the time trade-off approach.

Authors:  D N Churchill; G W Torrance; D W Taylor; C C Barnes; D Ludwin; A Shimizu; E K Smith
Journal:  Clin Invest Med       Date:  1987-01       Impact factor: 0.825

5.  Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment.

Authors:  M Krahn; C D Naylor; A S Basinski; A S Detsky
Journal:  Ann Intern Med       Date:  1991-08-15       Impact factor: 25.391

6.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

Authors: 
Journal:  Arch Intern Med       Date:  1988-01

7.  Cholesterol reduction and life expectancy. A model incorporating multiple risk factors.

Authors:  W C Taylor; T M Pass; D S Shepard; A L Komaroff
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

8.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245

Review 9.  Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level.

Authors:  A M Garber; H C Sox; B Littenberg
Journal:  Ann Intern Med       Date:  1989-04-15       Impact factor: 25.391

10.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.

Authors: 
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

View more
  7 in total

1.  Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey.

Authors:  N Steel
Journal:  BMJ       Date:  2000-05-27

Review 2.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 3.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

4.  Communicating risk reductions. Data were selectively used.

Authors:  J McMurray
Journal:  BMJ       Date:  1999-02-27

5.  Views on primary prevention of cardiovascular disease--an interview study with Swedish GPs.

Authors:  Louise Silwer; Rolf Wahlström; Cecilia Stålsby Lundborg
Journal:  BMC Fam Pract       Date:  2010-06-02       Impact factor: 2.497

Review 6.  Enlightened individual choice vs the public's health: rational prevention from whose perspective?

Authors:  L Goldman
Journal:  J Gen Intern Med       Date:  1995-03       Impact factor: 5.128

7.  When should hypertension be treated? The different perspectives of Canadian family physicians and patients.

Authors:  F A McAlister; A M O'Connor; G Wells; S A Grover; A Laupacis
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.